BDBM384457 US10590114, No. 144::US11111235, Compound 143::US11591316, Compound 143::US9932325, Example 143::US9932325, Example 144

SMILES CCNc1nc(Nc2cc(nn2C2CC2)C2(C)CCOC2=O)ncc1C(F)(F)F

InChI Key InChIKey=LXRVHITUSDCRCT-UHFFFAOYSA-N

Data  10 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 10 hits for monomerid = 384457   

TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384457(US10590114, No. 144 | US11111235, Compound 143 | U...)
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384457(US10590114, No. 144 | US11111235, Compound 143 | U...)
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Denali Therapautics

US Patent
LigandPNGBDBM384457(US10590114, No. 144 | US11111235, Compound 143 | U...)
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Homo sapiens (Human))
Denali Therapautics

US Patent
LigandPNGBDBM384457(US10590114, No. 144 | US11111235, Compound 143 | U...)
Affinity DataIC50: <30nMAssay Description:Materials: LRRK2 G2019S enzyme Substrate (LRRKtide) ATP TR-FRET dilution buffer pLRRKtide antibody 384-well...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384457(US10590114, No. 144 | US11111235, Compound 143 | U...)
Affinity DataIC50:  1.21nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384457(US10590114, No. 144 | US11111235, Compound 143 | U...)
Affinity DataIC50: <30nMAssay Description:Materials:LRRK2 G2019S enzymeSubstrate (LRRKtide)ATPTR-FRET dilution bufferpLRRKtide antibody384-well assay plateDMSOEnzyme Reaction Conditions50 mM ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384457(US10590114, No. 144 | US11111235, Compound 143 | U...)
Affinity DataIC50:  1.21nMAssay Description:Materials:LRRK2 G2019S enzymeSubstrate (LRRKtide)ATPTR-FRET dilution bufferpLRRKtide antibody384-well assay plateDMSOEnzyme Reaction Conditions50 mM ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384457(US10590114, No. 144 | US11111235, Compound 143 | U...)
Affinity DataIC50: <30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384457(US10590114, No. 144 | US11111235, Compound 143 | U...)
Affinity DataIC50: <30nMAssay Description:Compounds were prepared by initially diluting to 1 mM with DMSO. 35 μL of reference compound solution, 35 μL of test compound solution, and...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetLeucine-rich repeat serine/threonine-protein kinase 2 [G2019S](Homo sapiens (Human))
Denali Therapeutics

US Patent
LigandPNGBDBM384457(US10590114, No. 144 | US11111235, Compound 143 | U...)
Affinity DataIC50: <30nMAssay Description:Materials:LRRK2 G2019S enzymeSubstrate (LRRKtide)ATPTR-FRET dilution bufferpLRRKtide antibody384-well assay plateDMSOEnzyme Reaction Conditions50 mM ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent